MVMathias Vrolix

Mathias Vrolix

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mathias Vrolix has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reducing cardiovascular risk in Belgium through practical and measurable initiatives: a multidisciplinary expert-led call to action

    by Peter R. Sinnaeve, Frank Cools, Fabian Demeure, François Jouret, Noémie Ligot, Marijn Speeckaert, Philippe van de Borne, Johan Vansintejan, Klaas Vercruysse, Ann Verhaegen, et al.

    Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for an estimated 17.9 million deaths each year [1]. In Belgium alone, a country with a population of 11.7 million ...


  • Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial

    by Deborah M.F. van Den Buijs, Ella M. Poels, Endry Willems, Daan Cottens, Kevin Dotremont, Karen De Leener, Evelyne Meekers, Bert Ferdinande, Mathias Vrolix, Joseph Dens, et al.

    BACKGROUND: Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose. METHODS: In this single-center, prospective, open-label, core-laboratory blinded trial, a total of 30 patients with an aorto-ostial right coronary artery lesion were randomly assigned to either percutaneous coronary intervention with a preprocedural 3DCT or angiography-guided percutaneous coronary intervention. The optimal working view angle was determined by 3DCT in the intervention group and by the operators’ discretion in the control group. The primary end point was the percentage of patients without geographic mismatch, as determined by intravascular ultrasound. RESULTS: 3DCT-determined C-arm angles were heterogenous but, in general, more extreme left anterior oblique projections were used ( P P =0.06). The mean amount of procedural contrast ( P P =0.03), and median procedure time ( P =0.03) were significantly lower in the intervention group. The 3DCT scan was able to predict the calcium arc ( P P =0.003). CONCLUSIONS: Preprocedural 3DCT planning for percutaneous coronary intervention of aorto-ostial right coronary artery lesions allows for optimal stent positioning while reducing procedure time, contrast, and radiation dose. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05172323.


  • FFR pressure wire comparative study: piezoresistive versus optical sensor

    by Daan Cottens, Joren Maeremans, Mathias Vrolix, Johan Van Lierde, Jo Dens, Bert Ferdinande

    This study aimed to assess the reliability of pressure derived fractional flow reserve (FFR) measurement and the handling performance of the OptoWire Deux with an optical pressure sensor relative t...


  • Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY

    by Sergio Leonardi, Mattia Branca, Anna Franzone, Eugene McFadden, Raffaele Piccolo, Peter Jüni, Pascal Vranckx, Philippe Gabriel Steg, Patrick W. Serruys, Edouard Benit, et al.

    Background: Event adjudication by a clinical event committee (CEC) provides a standardized, independent outcome assessment. However, the added value of CEC to investigators reporting remains debated. GLASSY (GLOBAL LEADERS Adjudication Sub-Study) implemented, in a subset of the open-label, investigator-reported (IR) GLOBAL LEADERS trial, an independent adjudication process of reported and unreported potential outcome events (triggers). We describe metrics of GLASSY feasibility and efficiency, diagnostic accuracy of IR events, and their concordance with corresponding CEC-adjudicated events. Methods: We report the proportion of myocardial infarction, bleeding, stroke, and stent thrombosis triggers with sufficient evidence for assessment (feasibility) that were adjudicated as outcome events (efficiency), stratified by source (IR or non-IR). Using CEC-adjudicated events as criterion standard, we describe sensitivity, specificity, positive and negative predictive value, and global diagnostic accuracy of IR events. Using Gwet AC coefficient, we examine the concordance between IR- and corresponding CEC-adjudicated triggers. There was sufficient evidence for assessment for 2592 (98.3%) of 2636 triggers. Results: Overall, the adjudicated end point-to-trigger ratio was high and similar between IR- (88%) and non-IR–reported (87%) triggers. The global diagnostic accuracy and concordance between IR-reported and CEC-adjudicated outcome events was 0.70 (95% CI, 0.65–0.74) and 0.54 (95% CI, 0.45–0.62), respectively, for myocardial infarction; 0.77 (95% CI, 0.75–0.79) and 0.71 (95% CI, 0.68–0.74) for bleeding; 0.70 (95% CI, 0.62–0.79) and 0.59 (95% CI, 0.43–0.74) for stroke; 0.59 (95% CI, 0.52–0.66) and 0.39 (95% CI, 0.25–0.53) for stent thrombosis. For IR bleedings, the concordance with the CEC on type of events was generally weak. Conclusions: Implementing CEC adjudication in a pragmatic open-label trial with IR events is feasible and efficient. Our findings of modest global diagnostic accuracy for IR events and generally weak concordance between investigators and CEC support the role for CEC adjudication in such settings. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03231059.


  • Open Access

    First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial

    by Clemens von Birgelen, Taku Asano, Giovanni Amoroso, Adel Aminian, Salvatore Brugaletta, Mathias Vrolix, Rosana Hernandez-Antolín, Pim van de Harst, Andres Iñiguez, Luc Janssens, et al.

    A second iteration of a sirolimus-eluting stent (SES) that has a biodegradable PLGA polymer coating with an electrografting base layer on a thin-strut (80 µm) cobalt-chromium platform (BuMA Supreme; SINOMED, Tianjin, China) has been developed. This first-in-man trial aimed to assess the efficacy and safety of the novel device. This randomised, multicentre, single-blinded, non-inferiority trial compared the BuMA Supreme SES versus a contemporary durable polymer zotarolimus-eluting stent (ZES) in terms of angiographic in-stent late lumen loss (LLL) at nine-month follow-up as the primary endpoint. A total of 170 patients were randomly allocated to treatment with either SES (n=83) or ZES (n=87). At nine-month angiographic follow-up, in-stent LLL was 0.29±0.33 mm in the SES group and 0.14±0.37 mm in the ZES group (pnon-inferiority=0.45). The in-stent percent diameter stenosis and the binary restenosis rate of the two treatment arms were similar (19.2±12.0% vs. 16.1±12.6%, p=0.09, and 3.3% vs. 4.4%, p=1.00, respectively). At 12-month clinical follow-up, there was no difference between treatment arms with regard to the device-oriented composite clinical endpoint (4.9% vs. 5.7%; p=0.72). The PIONEER trial did not meet its primary endpoint in terms of in-stent LLL at nine-month follow-up. However, this result did not translate into any increase in restenosis rate or impairment in 12-month clinical outcomes.


  • Open Access

    STENTYS Self-Apposing® sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial

    by Robert-Jan M. van Geuns, Tuncay Yetgin, Alessio La Manna, Corrado Tamburino, Géraud Souteyrand, Pascal Motreff, Karel T. Koch, Mathias Vrolix, Alexander Ijsselmuiden, Giovanni Amoroso, et al.

    The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)


  • Reply

    by Jozef Bartunek, Atta Behfar, Dariouch Dolatabadi, Marc Vanderheyden, Miodrag Ostojic, Jo Dens, Badih El Nakadi, Marko Banovic, Branko Beleslin, Mathias Vrolix, et al.


  • Open Access

    Long-term follow-up after percutaneous coronary intervention with polytetrafl uoroethylene-covered Symbiot™ stents compared to bare metal stents, with and without FilterWire™ embolic protection, in diseased saphenous vein grafts

    by Johan Bennett, Jo Dens, Francis Stammen, Patrick Coussement, Luc Janssens, Marc Claeys, Mathias Vrolix, Peter Sinnaeve, Christophe Dubois, Walter Desmet

    The long-term clinical outcome of covered stents in the percutaneous treatment of diseased saphenous vein graft (SVG) has been disappointing. The single self-expanding polytetrafluoroethylene (PTFE)-covered Symbiot stent with a unique profile may present advantages that translate into superior long-term clinical outcomes. This study evaluated the safety, effectiveness and clinical outcome of the Symbiot covered stent system (Boston Scientific, Natick, Mass.) and FilterWire EX (Boston Scientific, Natick, Mass.) versus bare metal stents (BMS) in SVG intervention. Between January 2003 and August 2005, 90 patients with degenerative SVG lesions were prospectively randomized at 6 study sites to Symbiot implantation (n = 30), BMS with FilterWire as embolic protection device (EPD, n = 30), or BMS without EPD (control group, n = 30). The primary end point was reduction in peri-procedural cardiac enzyme rise. The major secondary end points were in-hospital, 6-month and long-term target vessel failure rates, defined as the cumulative of death, myocardial infarction and clinically driven target lesion revascularization. There was no significant reduction in median [IQR] post-procedural troponin-I rise in the Symbiot group compared to the FilterWire or the control group (0.08 [0-1.40] microg/l; 0.06 [0-0.28] microg/l; and 0.04 [0-0.31] microg/l, P = 0.58). At 7.4 +/- 1.3 (mean +/- SD) years, there were numerically less deaths in the Symbiot group, although this did not reach statistical significance (P = 0.20). There was no significant difference in TVF-free survival between the treatment groups (P = 0.98). This study failed to show a procedural or long-term clinical advantage for the Symbiot PTFE-covered stent in the treatment of degenerated SVG.